ArticleScientific reports2025
Associations between four insulin resistance (IR) surrogates and the risk of small cell lung cancer (SCLC).
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance (IR) has been shown to be correlated with increased cancer risk. Nevertheless, few studies have explored the relationship between IR and small cell lung cancer (SCLC). The triglyceride glucose (TyG) index, TyG index with body mass index (TyG-BMI), triglyceride/high-density lipoprotein cholesterol ratio (TG/HDL-C), and metabolic score for IR (METS-IR) are recognized as reliable indicators for evaluating IR. In our investigation, 235 patients with pathologically confirmed SCLC were enrolled, along with 235 healthy individuals matched for age and sex as controls. Univariate binary logistic regression analyses revealed a significant association between elevated levels of all IR surrogates and the risk of SCLC. This finding persisted even after adjusting for other established high-risk factors. Concurrently, a progressive increase in the incidence of SCLC was observed across the tertiles of the TyG index, TyG-BMI, TG/HDL-C, and METS-IR. Furthermore, this article is the first to conclude that the four IR surrogates did not significantly differ across different stages of SCLC, implying that IR might exert a greater influence on the onset than on the progression of SCLC. Among these factors, TG/HDL-C has emerged as the most effective predictor of SCLC. Consequently, lifestyle modifications and pharmacological interventions should be actively pursued in individuals with IR to mitigate their risk of developing SCLC. Our findings also offer a promising avenue for the identification of novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.